DOCSLIB.ORG

Biomarkers in Community-Acquired Pneumonia: Still Searching for the One

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biomarkers in Community-Acquired Pneumonia: Still Searching for the One EDITORIAL | RESPIRATORY INFECTION Biomarkers in community-acquired pneumonia: still searching for the one Oriol Sibila 1,2 and Marcos I. Restrepo3 Affiliations: 1Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 2Institut d´Investigació Biomèdica Sant Pau (IIB Sant Pau), Barcelona, Spain. 3Division of Pulmonary Diseases and Critical Care Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. Correspondence: Oriol Sibila, Servei de Pneumologia, Hospital de la Santa Creu i Sant Pau, C/ Sant Antoni M. Claret 167, 08025 Barcelona, Spain. E-mail: [email protected] @ERSpublications Fibroblast growth factor 21 (FGF21) predicts severity of illness, clinical stability and mortality in community-acquired pneumonia. Validation is needed to confirm the application of FGF21 in clinical practice. http://ow.ly/SYI730nuRc1 Cite this article as: Sibila O, Restrepo MI. Biomarkers in community-acquired pneumonia: still searching for the one. Eur Respir J 2019; 53: 1802469 [https://doi.org/10.1183/13993003.02469-2018]. Community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality worldwide [1]. Despite advances in antibiotic treatment and medical care, the mortality of CAP is still high in hospitalised patients, especially in those with severe illness [2]. Appropriate initial severity assessment is a crucial step in pneumonia management, since it has been demonstrated that an early recognition of severe CAP patients improves their clinical outcomes [3]. Several tools have been developed to evaluate disease severity, in particular focusing on predicting hospital admission and mortality [4]. However, recent studies have showed that most of these scores are not used routinely in clinical practice and may be inadequate tools to guide appropriate antibiotic treatment [5, 6]. Biomarkers are biological markers that can be measured accurately and reproducibly from patients’ samples. In pneumonia, several studies have evaluated the role of biomarkers in different important clinical areas, such as diagnosis of pneumonia, aetiology, risk stratification and triage decision, severity of illness and initiation/duration/discontinuation of antibiotic therapy [7]. Most of these studies focused on inflammatory markers that reflect the interaction between the micro-organism and the host, which is crucial in CAP prognosis and severity of disease [8]. The two most common inflammatory biomarkers are C-reactive protein (CRP) and procalcitonin (PCT). However, other biomarkers with less available evidence have been tested for a wide range of clinical outcomes, and include sTREM (soluble triggering receptor expressed on myeloid cells) [9, 10], pro-adrenomedullin [11, 12], pro-atrial natriuretic peptide [13, 14], pro-vasopressin [15, 16], surfactant protein-D, human cartilage glycoprotein YKL-40 and chemokine ligand 18 [17], endocan [18], barrier-stabilising angiopoietins 1 and 2 [19], or markers of neutrophil extracellular traps [20]. Figure 1 summarises the most common biomarkers evaluated and their potential role in assessing different clinical outcomes in patients with CAP. In this issue of European Respiratory Journal,EBRAHIMI et al. [21] studied the prognostic value in CAP patients of fibroblast growth factor 21 (FGF21), a peptide hormone that has been shown to act as a metabolite regulator of glucose homeostasis, ketogenesis, insulin sensitivity and lipid metabolism [22]. Several organs synthesise FGF21, including the liver, brown adipose tissue, inguinal white adipose tissue, gonadal white adipose tissue, muscle, pancreas and heart. Therefore, it can act on multiple target tissues in either a paracrine or an endocrine fashion. It is postulated that FGF21 may play an important role in the Received: Dec 31 2018 | Accepted after revision: Jan 19 2019 The content of this work is not subject to copyright. Design and branding are copyright ©ERS 2019 https://doi.org/10.1183/13993003.02469-2018 Eur Respir J 2019; 53: 1802469 RESPIRATORY INFECTION | O. SIBILA AND M.I. RESTREPO Pro-ADM Endocan Pro-ANP Pro-VNP Diagnosis of SP-D Severity of illness pneumonia YKL-40 sTREM CCL18 CRP Diagnosis of Risk of mortality bacterial infection PCT Initiation/duration of Ang-1 Clinical stability antibiotic therapy Ang-2 NETs FGF21 FIGURE 1 Inflammatory biomarkers and their relationship with community-acquired pneumonia outcomes most studied in the past 10 years. sTREM: soluble triggering receptor expressed on myeloid cells; CRP: C-reactive protein; PCT: procalcitonin; Ang: barrier-stabilising angiopoietin; pro-ADM: pro-adrenomedullin; pro-ANP: pro-atrial natriuretic peptide; pro-VNP: pro-vasopressin; SP-D: surfactant protein-D; YKL-40: human cartilage glycoprotein YKL-40; CCL18: chemokine ligand 18; NET: neutrophil extracellular trap. immunoregulation of pro- and anti-inflammatory mediators in systemic inflammatory states such as pneumonia. Using samples and clinical data of two previous well-defined cohorts of hospitalised CAP patients, the authors found that FGF21 levels at admission were related to disease severity and identify patients at risk of 30-day all-cause mortality with superior discriminate power compared to than routine markers such as CRP, PCT or white cell count. The prognostic performance of FGF21 for the prediction of 30-day mortality was better than commonly used clinical scores such as CURB-65 and comparable to the Pneumonia Severity Index (PSI). In addition, adjunct treatment with corticosteroids, which potentially improved clinical outcomes in these patients [23], led to decreasing FGF21 levels, which is related to clinical stability. These findings are novel and suggest that the determination of FGF21 on admission and during hospitalisation might provide information regarding the severity of CAP, time to clinical stability and risk of short-term mortality. However, it is important to remark that the use of FGF21 as a CAP biomarker in clinical practice is still undermined by many uncertainties and questions. First, it is unclear the equipment that would be needed and the cost related to measure FGF21. This may bring difficulties with implementation in a “real world scenario” compared to the easily accessible and cost-effective. Second, the identification of clinically relevant cut-off values is critical in the interpretation and adoption of this new biomarker. Third, as seen with corticosteroids, comorbid conditions or other concomitant treatments may potentially affect FGF21 levels. And finally, validation studies are needed in order to prove that FGF21 is here to compete against other biomarkers, before final adoption in clinical practice. In summary, FGF21 is a novel biomarker tested to predict CAP severity. However, time and new evidence will tell whether FGF21 will become a biomarker that will assist clinicians in decision-making regarding care for patients with CAP, and to help improve patients’ clinical outcomes. It is encouraging to see a growing trend in identifying new molecules and novel biomarkers for a neglected disease that affects millions of patients around the world [24]. Conflict of interest: None declared. References 1 Waterer G. Community-acquired pneumonia: a global perspective. Semin Respir Crit Care Med 2016; 37: 799–805. 2 Kolditz M, Braeken D, Ewig S, et al. Severity assessment and the immediate and long-term prognosis in community-acquired pneumonia. Semin Respir Crit Care Med 2016; 37: 886–896. https://doi.org/10.1183/13993003.02469-2018 2 RESPIRATORY INFECTION | O. SIBILA AND M.I. RESTREPO 3 Sibila O, Restrepo MI, Anzueto A. What is the best antimicrobial treatment for severe community-acquired pneumonia (including the role of steroids and statins and other immunomodulatory agents). Infect Dis Clin North Am 2013; 27: 133–147. 4 Fernandez JF, Sibila O, Restrepo MI. Predicting ICU admission in community-acquired pneumonia: clinical scores and biomarkers. Expert Rev Clin Pharmacol 2012; 5: 445–458. 5 Serisier DJ, Williams S, Bowler SD. Australasian respiratory and emergency physicians do not use the pneumonia severity index in community-acquired pneumonia. Respirology 2013; 18: 291–296. 6 Singanayagam A, Aliberti S, Cillóniz C, et al. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. Eur Respir J 2017; 50: 1602306. 7 Sungurlu S, Balk RA. The role of biomarkers in the diagnosis and management of pneumonia. Clin Chest Med 2018; 39: 691–701. 8 Guertler C, Wirz B, Christ-Crain M, et al. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J 2011; 37: 1439–1446. 9 Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350: 451–458. 10 Esposito S, Di Gangi M, Cardinale F, et al. Sensitivity and specificity of soluble triggering receptor expressed on myeloid cells-1, midregional proatrial natriuretic peptide and midregional proadrenomedullin for distinguishing etiology and to assess severity in community-acquired pneumonia. PLoS One 2016; 11: e0163262. 11 Krüger S, Ewig S, Giersdorf S, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia. Am J Respir Crit Care Med 2010; 182: 1426–1434. 12 Bello S, Lasierra AB, Mincholé E, et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology. Eur Respir J 2012; 39: 1144–1155. 13 Müller B, Süess E, Schuetz P, et al. Circulating
Load more

Recommended publications
  • Discovery of Orphan Receptor Tie1 and Angiopoietin Ligands Ang1 and Ang4 As Novel GAG-Binding Partners
    78 Chapter 3 Discovery of Orphan Receptor Tie1 and Angiopoietin Ligands Ang1 and Ang4 as Novel GAG-Binding Partners 79 3.1 Abstract The Tie/Ang signaling axis is necessary for proper vascular development and remodeling. However, the mechanisms that modulate signaling through this receptor tyrosine kinase pathway are relatively unclear. In particular, the role of the orphan receptor Tie1 is highly disputed. Although this protein is required for survival, Tie1 has been found both to inhibit and yet be necessary for Tie2 signaling. While differing expression levels have been put forth as an explanation for its context-specific activity, the lack of known endogenous ligands for Tie1 has severely hampered understanding its molecular mode of action. Here we describe the discovery of orphan receptor Tie1 and angiopoietin ligands Ang1 and Ang4 as novel GAG binding partners. We localize the binding site of GAGs to the N- terminal region of Tie1, which may provide structural insights into the importance of this interaction regarding the formation of Tie1-Tie2 heterodimerization. Furthermore, we use our mutagenesis studies to guide the generation of a mouse model that specifically ablates GAG-Tie1 binding in vivo for further characterization of the functional outcomes of GAG-Tie1 binding. We also show that GAGs can form a trimeric complex with Ang1/4 and Tie2 using our microarray technology. Finally, we use our HaloTag glycan engineering platform to modify the cell surface of endothelial cells and demonstrate that HS GAGs can potentiate Tie2 signaling in a sulfation-specific manner, providing the first evidence of the involvement of HS GAGs in Tie/Ang signaling and delineating further the integral role of HS GAGs in angiogenesis.
    [Show full text]
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin
    Published OnlineFirst August 25, 2010; DOI: 10.1158/1078-0432.CCR-10-0613 Clinical Imaging, Diagnosis, Prognosis Cancer Research Gene Expression Analysis Identifies Potential Biomarkers of Neurofibromatosis Type 1 Including Adrenomedullin Trent R. Hummel1, Walter J. Jessen1, Shyra J. Miller1, Lan Kluwe4, Victor F. Mautner4, Margaret R. Wallace5, Conxi Lázaro6, Grier P. Page7, Paul F. Worley8, Bruce J. Aronow2, Elizabeth K. Schorry3, and Nancy Ratner1 Abstract Purpose: Plexiform neurofibromas (pNF) are Schwann cell tumors found in a third of individuals with neurofibromatosis type 1 (NF1). pNF can undergo transformation to malignant peripheral nerve sheath tumors (MPNST). There are no identified serum biomarkers of pNF tumor burden or transformation to MPNST. Serum biomarkers would be useful to verify NF1 diagnosis, monitor tumor burden, and/or detect transformation. Experimental Design: We used microarray gene expression analysis to define 92 genes that encode putative secreted proteins in neurofibroma Schwann cells, neurofibromas, and MPNST. We validated dif- ferential expression by quantitative reverse transcription-PCR, Western blotting, and ELISA assays in cell conditioned medium and control and NF1 patient sera. Results: Of 13 candidate genes evaluated, only adrenomedullin (ADM) was confirmed as differentially expressed and elevated in serum of NF1 patients. ADM protein concentrati on was further elevated in serum of a small sampling of NF1 patients with MPNST. MPNST cell conditioned medium, containing ADM and hepatocyte growth factor, stimulated MPNST migration and endothelial cell proliferation. Conclusions: Thus, microarray analysis identifies potential serum biomarkers for disease, and ADM is a serum biomarker of NF1. ADM serum levels do not seem to correlate with the presence of pNFs but may be a biomarker of transformation to MPNST.
    [Show full text]
  • Pdgfrβ Regulates Adipose Tissue Expansion and Glucose
    1008 Diabetes Volume 66, April 2017 Yasuhiro Onogi,1 Tsutomu Wada,1 Chie Kamiya,1 Kento Inata,1 Takatoshi Matsuzawa,1 Yuka Inaba,2,3 Kumi Kimura,2 Hiroshi Inoue,2,3 Seiji Yamamoto,4 Yoko Ishii,4 Daisuke Koya,5 Hiroshi Tsuneki,1 Masakiyo Sasahara,4 and Toshiyasu Sasaoka1 PDGFRb Regulates Adipose Tissue Expansion and Glucose Metabolism via Vascular Remodeling in Diet-Induced Obesity Diabetes 2017;66:1008–1021 | DOI: 10.2337/db16-0881 Platelet-derived growth factor (PDGF) is a key factor in The physiological roles of the vasculature in adipose tissue angiogenesis; however, its role in adult obesity remains have been attracting interest from the viewpoint of adipose unclear. In order to clarify its pathophysiological role, tissue expansion and chronic inflammation (1,2). White we investigated the significance of PDGF receptor b adipose tissue (WAT) such as visceral fat possesses the (PDGFRb) in adipose tissue expansion and glucose unique characteristic of plasticity; its volume may change metabolism. Mature vessels in the epididymal white several fold even after growth depending on nutritional adipose tissue (eWAT) were tightly wrapped with peri- conditions. Enlarged adipose tissue is chronically exposed cytes in normal mice. Pericyte desorption from vessels to hypoxia (3,4), which stimulates the production of angio- and the subsequent proliferation of endothelial cells genic factors for the supplementation of nutrients and were markedly increased in the eWAT of diet-induced oxygen to the newly enlarged tissue area (5). Selective ab- obese mice. Analyses with flow cytometry and adipose lation of the vasculature in WAT by apoptosis-inducible tissue cultures indicated that PDGF-B caused the de- peptides or the systemic administration of angiogenic in- PATHOPHYSIOLOGY tachment of pericytes from vessels in a concentration- hibitors has been shown to reduce WAT volumes and result dependent manner.
    [Show full text]
  • FGF21 Acts As a Negative Regulator of Bile Acid Synthesis
    237 2 Journal of M M Chen, C Hale et al. FGF21 negative regulator of bile 237:2 139–152 Endocrinology acid metabolism RESEARCH FGF21 acts as a negative regulator of bile acid synthesis Michelle M Chen*, Clarence Hale*, Shanaka Stanislaus, Jing Xu and Murielle M Véniant Department of Cardiometabolic Disorders, Amgen Inc., Thousand Oaks, California, USA Correspondence should be addressed to M M Véniant: [email protected] *(M M Chen and C Hale contributed equally to this work) Abstract Fibroblast growth factor 21 (FGF21) is a potent regulator of glucose and lipid Key Words homeostasis in vivo; its most closely related subfamily member, FGF19, is known to be a f FGF21 critical negative regulator of bile acid synthesis. To delineate whether FGF21 also plays a f Fc-fusion protein functional role in bile acid metabolism, we evaluated the effects of short- and long-term f β-klotho binding exposure to native FGF21 and long-acting FGF21 analogs on hepatic signal transduction, f bile acid gene expression and enterohepatic bile acid levels in primary hepatocytes and in rodent and monkey models. FGF21 acutely induced ERK phosphorylation and inhibited Cyp7A1 mRNA expression in primary hepatocytes and in different rodent models, although less potently than recombinant human FGF19. Long-term administration of FGF21 in mice fed a standard chow diet resulted in a 50–60% decrease in bile acid levels in the liver and small intestines and consequently a 60% reduction of bile acid pool size. In parallel, colonic and fecal bile acid was decreased, whereas fecal cholesterol and fatty acid excretions were elevated.
    [Show full text]
  • FGF Signaling Network in the Gastrointestinal Tract (Review)
    163-168 1/6/06 16:12 Page 163 INTERNATIONAL JOURNAL OF ONCOLOGY 29: 163-168, 2006 163 FGF signaling network in the gastrointestinal tract (Review) MASUKO KATOH1 and MASARU KATOH2 1M&M Medical BioInformatics, Hongo 113-0033; 2Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo 104-0045, Japan Received March 29, 2006; Accepted May 2, 2006 Abstract. Fibroblast growth factor (FGF) signals are trans- Contents duced through FGF receptors (FGFRs) and FRS2/FRS3- SHP2 (PTPN11)-GRB2 docking protein complex to SOS- 1. Introduction RAS-RAF-MAPKK-MAPK signaling cascade and GAB1/ 2. FGF family GAB2-PI3K-PDK-AKT/aPKC signaling cascade. The RAS~ 3. Regulation of FGF signaling by WNT MAPK signaling cascade is implicated in cell growth and 4. FGF signaling network in the stomach differentiation, the PI3K~AKT signaling cascade in cell 5. FGF signaling network in the colon survival and cell fate determination, and the PI3K~aPKC 6. Clinical application of FGF signaling cascade in cell polarity control. FGF18, FGF20 and 7. Clinical application of FGF signaling inhibitors SPRY4 are potent targets of the canonical WNT signaling 8. Perspectives pathway in the gastrointestinal tract. SPRY4 is the FGF signaling inhibitor functioning as negative feedback apparatus for the WNT/FGF-dependent epithelial proliferation. 1. Introduction Recombinant FGF7 and FGF20 proteins are applicable for treatment of chemotherapy/radiation-induced mucosal injury, Fibroblast growth factor (FGF) family proteins play key roles while recombinant FGF2 protein and FGF4 expression vector in growth and survival of stem cells during embryogenesis, are applicable for therapeutic angiogenesis. Helicobacter tissues regeneration, and carcinogenesis (1-4).
    [Show full text]
  • FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk Between Liver and Brain During Prolonged Fasting
    4064 Diabetes Volume 63, December 2014 Qingning Liang,1,2 Ling Zhong,1,2 Jialiang Zhang,1,2 Yu Wang,1,3 Stefan R. Bornstein,4 Chris R. Triggle,5 Hong Ding,5 Karen S.L. Lam,1,2 and Aimin Xu1,2,3 FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk Between Liver and Brain During Prolonged Fasting Diabetes 2014;63:4064–4075 | DOI: 10.2337/db14-0541 Hepatic gluconeogenesis is a main source of blood glucose Hepatic gluconeogenesis is tightly controlled by counter- during prolonged fasting and is orchestrated by endocrine regulatory hormones such as glucagon, cortisol, and insulin, and neural pathways. Here we show that the hepatocyte- via regulating the expression of key gluconeogenic enzymes, secreted hormone fibroblast growth factor 21 (FGF21) including glucose 6 phosphatase (G6Pase) and phospho- induces fasting gluconeogenesis via the brain-liver axis. enolpyruvate carboxykinase (PEPCK). Fibroblast growth Prolonged fasting induces activation of the transcrip- factor 21 (FGF21), a metabolic regulator mainly secreted tion factor peroxisome proliferator–activated receptor a a from the liver in response to fasting and starvation under (PPAR ) in the liver and subsequent hepatic produc- – tion of FGF21, which enters into the brain to activate the the control of the nuclear receptor peroxisome proliferator hypothalamic-pituitary-adrenal (HPA) axis for release of activated receptor a (PPARa), plays a critical role in main- corticosterone, thereby stimulating hepatic gluconeogene- taining energy homeostasis and insulin sensitivity in both METABOLISM sis. Fasted FGF21 knockout (KO) mice exhibit severe rodents and nonhuman primates (1–6). A therapeutic dose hypoglycemia and defective hepatic gluconeogenesis due of FGF21 decreased blood glucose in diabetic animals with- to impaired activation of the HPA axis and blunted release out causing hypoglycemia (4).
    [Show full text]
  • As a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial
    cells Review Erythropoietin (EPO) as a Key Regulator of Erythropoiesis, Bone Remodeling and Endothelial Transdifferentiation of Multipotent Mesenchymal Stem Cells (MSCs): Implications in Regenerative Medicine Asterios S. Tsiftsoglou Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; [email protected] Abstract: Human erythropoietin (EPO) is an N-linked glycoprotein consisting of 166 aa that is pro- duced in the kidney during the adult life and acts both as a peptide hormone and hematopoietic growth factor (HGF), stimulating bone marrow erythropoiesis. EPO production is activated by hypoxia and is regulated via an oxygen-sensitive feedback loop. EPO acts via its homodimeric erythropoietin receptor (EPO-R) that increases cell survival and drives the terminal erythroid mat- uration of progenitors BFU-Es and CFU-Es to billions of mature RBCs. This pathway involves the activation of multiple erythroid transcription factors, such as GATA1, FOG1, TAL-1, EKLF and BCL11A, and leads to the overexpression of genes encoding enzymes involved in heme biosynthesis Citation: Tsiftsoglou, A.S. and the production of hemoglobin. The detection of a heterodimeric complex of EPO-R (consist- Erythropoietin (EPO) as a Key ing of one EPO-R chain and the CSF2RB β-chain, CD131) in several tissues (brain, heart, skeletal Regulator of Erythropoiesis, Bone muscle) explains the EPO pleotropic action as a protection factor for several cells, including the Remodeling and Endothelial multipotent MSCs as well as cells modulating the innate and adaptive immunity arms. EPO induces Transdifferentiation of Multipotent the osteogenic and endothelial transdifferentiation of the multipotent MSCs via the activation of Mesenchymal Stem Cells (MSCs): EPO-R signaling pathways, leading to bone remodeling, induction of angiogenesis and secretion Implications in Regenerative of a large number of trophic factors (secretome).
    [Show full text]
  • Erythropoietin and Its Angiogenic Activity
    International Journal of Molecular Sciences Review Erythropoietin and Its Angiogenic Activity Patrícia Kimáková 1,†, Peter Solár 1,*,† ID , Zuzana Solárová 2, Radovan Komel 3 and Nataša Debeljak 3 ID 1 Laboratory of Cell Biology, Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Košice 04001, Slovak; [email protected] 2 Institute of Pharmacology, Faculty of Medicine, P.J. Šafárik University in Košice, Košice 04001, Slovak; [email protected] 3 Medical Centre for Molecular Biology, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana SI-1000, Slovenia; [email protected] (R.K.); [email protected] (N.D.) * Correspondence: [email protected]; Tel.: +421-55-234-1199, Fax: +421-55-622-2124 † These authors contributed equally to this work. Received: 26 May 2017; Accepted: 11 July 2017; Published: 13 July 2017 Abstract: Erythropoietin (EPO) is the main hematopoietic hormone acting on progenitor red blood cells via stimulation of cell growth, differentiation, and anti-apoptosis. However, its receptor (EPOR) is also expressed in various non-hematopoietic tissues, including endothelium. EPO is a pleiotropic growth factor that exhibits growth stimulation and cell/tissue protection on numerous cells and tissues. In this article we review the angiogenesis potential of EPO on endothelial cells in heart, brain, and leg ischemia, as well as its role in retinopathy protection and tumor promotion. Furthermore, the effect of EPO on bone marrow and adipose tissue is also discussed. Keywords: erythropoietin; erythropoietin receptor; endothelial; angiogenesis; cancer 1. Introduction Erythropoietin (EPO) is the main hematopoietic cytokine that regulates the formation of red blood cells in the process of hematopoiesis [1].
    [Show full text]
  • A Bioinformatics Model of Human Diseases on the Basis Of
    SUPPLEMENTARY MATERIALS A Bioinformatics Model of Human Diseases on the basis of Differentially Expressed Genes (of Domestic versus Wild Animals) That Are Orthologs of Human Genes Associated with Reproductive-Potential Changes Vasiliev1,2 G, Chadaeva2 I, Rasskazov2 D, Ponomarenko2 P, Sharypova2 E, Drachkova2 I, Bogomolov2 A, Savinkova2 L, Ponomarenko2,* M, Kolchanov2 N, Osadchuk2 A, Oshchepkov2 D, Osadchuk2 L 1 Novosibirsk State University, Novosibirsk 630090, Russia; 2 Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk 630090, Russia; * Correspondence: [email protected]. Tel.: +7 (383) 363-4963 ext. 1311 (M.P.) Supplementary data on effects of the human gene underexpression or overexpression under this study on the reproductive potential Table S1. Effects of underexpression or overexpression of the human genes under this study on the reproductive potential according to our estimates [1-5]. ↓ ↑ Human Deficit ( ) Excess ( ) # Gene NSNP Effect on reproductive potential [Reference] ♂♀ NSNP Effect on reproductive potential [Reference] ♂♀ 1 increased risks of preeclampsia as one of the most challenging 1 ACKR1 ← increased risk of atherosclerosis and other coronary artery disease [9] ← [3] problems of modern obstetrics [8] 1 within a model of human diseases using Adcyap1-knockout mice, 3 in a model of human health using transgenic mice overexpressing 2 ADCYAP1 ← → [4] decreased fertility [10] [4] Adcyap1 within only pancreatic β-cells, ameliorated diabetes [11] 2 within a model of human diseases
    [Show full text]
  • Growth Factors Acting Via Endothelial Cell-Specific Receptor Tyrosine Kinases: Vegfs, Angiopoietins, and Ephrins in Vascular Development
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, Angiopoietins, and ephrins in vascular development Nicholas W. Gale1 and George D. Yancopoulos Regeneron Pharmaceuticals, Inc., Tarrytown, New York 10591-6707 USA The term ‘vasculogenesis’ refers to the earliest stages of since been shown to be a critical regulator of endothelial vascular development, during which vascular endotheli- cell development. Not surprisingly, the specificity of al cell precursors undergo differentiation, expansion, and VEGF-A for the vascular endothelium results from the coalescence to form a network of primitive tubules restricted distribution of VEGF-A receptors to these (Risau 1997). This initial lattice, consisting purely of en- cells. The need to regulate the multitude of cellular in- dothelial cells that have formed rather homogenously teractions involved during vascular development sug- sized interconnected vessels, has been referred to as the gested that VEGF-A might not be alone as an endothelial primary capillary plexus. The primary plexus is then re- cell-specific growth factor. Indeed, there has been a re- modeled by a process referred to as angiogenesis (Risau cent explosion in the number of growth factors that spe- 1997), which involves the sprouting, branching, and dif- cifically act on the vascular endothelium. This explosion ferential growth of blood vessels to form the more ma- involves the VEGF family, which now totals at least five ture appearing vascular patterns seen in the adult organ- members. In addition, an entirely unrelated family of ism. This latter phase of vascular development also in- growth factors, known as the Angiopoietins, recently has volves the sprouting and penetration of vessels into been identified as acting via endothelial cell-specific re- previously avascular regions of the embryo, and also the ceptors known as the Ties.
    [Show full text]
  • A Global Transcriptome Analysis Reveals Molecular Hallmarks of Neural Stem Cell Death, Survival, and Differentiation in Response to Partial FGF-2 and EGF Deprivation
    A Global Transcriptome Analysis Reveals Molecular Hallmarks of Neural Stem Cell Death, Survival, and Differentiation in Response to Partial FGF-2 and EGF Deprivation Vanesa Nieto-Este´ vez1,2, Jaime Pignatelli1,2, Marcos J. Arau´ zo-Bravo3, Anahı´ Hurtado-Chong1, Carlos Vicario-Abejo´ n1,2* 1 Instituto Cajal, Consejo Superior de Investigaciones Cientı´ficas (CSIC), Madrid, Spain, 2 Centro de Investigacio´nBiome´dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain, 3 Laboratory of Computational Biology and Bioinformatics, Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, Muenster, Germany Abstract Neurosphere cell culture is a commonly used model to study the properties and potential applications of neural stem cells (NSCs). However, standard protocols to culture NSCs have yet to be established, and the mechanisms underlying NSC survival and maintenance of their undifferentiated state, in response to the growth factors FGF-2 and EGF are not fully understood. Using cultures of embryonic and adult olfactory bulb stem cells (eOBSCs and aOBSCs), we analyzed the consequences of FGF-2 and EGF addition at different intervals on proliferation, cell cycle progression, cell death and differentiation, as well as on global gene expression. As opposed to cultures supplemented daily, addition of FGF-2 and EGF every 4 days significantly reduced the neurosphere volume and the total number of cells in the spheres, mainly due to increased cell death. Moreover, partial FGF-2 and EGF deprivation produced an increase in OBSC differentiation during the proliferative phase. These changes were more evident in aOBSC than eOBSC cultures. Remarkably, these effects were accompanied by a significant upregulation in the expression of endogenous Fgf-2 and genes involved in cell death and survival (Cryab), lipid catabolic processes (Pla2g7), cell adhesion (Dscaml1), cell differentiation (Dscaml1, Gpr17, S100b, Ndrg2) and signal transduction (Gpr17, Ndrg2).
    [Show full text]